ADC Contract Manufacturing Market Size & Competitors

The ADC contract manufacturing market is estimated to grow from 2.13 billion in the current year to USD 3.21 billion by 2035 at a CAGR of 4.6% during the forecast period, till 2035.

Scale of Operation

Clinical Scale
Commercial Scale

Process Component

Tubulin Inhibitors
Topoisomerase Inhibitors
DNA Damaging Agents
Others

Type of Payload

Tubulin Inhibitors
Topoisomerase Inhibitors
DNA Damaging Agents
Others

Antibody Isotype

IgG1
IgG4
Others

Target Indication

Solid Tumors
Hematological Malignancies

Type of Linker

Valine-citrulline
SMCC
Hydrazone
Maleimide
Maleimidocaproyl
Tetrapeptide-based linker
Peptide Linker
Others

Antibody Origin

Humanized
Chimeric
Human
Others

Key Geographical Regions

North America
US
Canada
Rest of North America
Europe
UK
Spain
Italy
Germany
France
Rest of Europe
Asia-Pacific and Rest of the World
China
Japan
India
South Korea
Australia
Argentina
Brazil
Chile
Columbia
Israel
Kenya
Peru
South Africa
Turkey
Saudi Arabia
Rest of Asia-Pacific and rest of the world

ADC CONTRACT MANUFACTURING MARKET: GROWTH AND TRENDS

Antibody drug conjugates (ADCs) have shown remarkable promise in recent years for the treatment of various cancers, encompassing both solid tumors and hematological malignancies. These intricate molecules, consisting of an antibody linked to biologically active, cytotoxic substances via chemical connectors, demonstrate improved stability, target specificity, tumor selectivity, and pharmacokinetic characteristics.

At present, the ADC pipeline comprises more than 614 drug candidates in clinical trial assessment, in addition to 28 ADC therapeutic programs that have received approval from different regulatory bodies. The production process for ADC necessitates specialized knowledge and the application of advanced technologies, both of which are cost intensive. Consequently, ADC developers favor delegating manufacturing tasks to ADC contract manufacturers. By utilizing the expertise, resources, and production facilities of these CMOs, developers can streamline costs and speed up schedules. Due to the rising demand for ADCs and the growing tendency for drug developers to outsource operations, the ADC contract manufacturing market is expected to experience significant growth throughout the forecast period.

ADC CONTRACT MANUFACTURING MARKET: KEY INSIGHTS

The report delves into the current state of the ADC contract manufacturing market and identifies potential growth opportunities within the industry. Some key findings from the report include:

The current market landscape features a presence of close to 35 companies that claim to have the required capabilities to offer contract manufacturing and conjugation services for antibody drug conjugates, worldwide.
Majority (~65%) of the manufacturers offer different types of services across all scales of operation, in order to become one-stop shops for mitigating technical challenges such as technology transfer and scale-up for clients.

Stakeholders are actively upgrading their existing capabilities in order to enhance their respective portfolios and gain a competitive edge over other players active in the ADC contract manufacturing domain.
Industry players are undertaking significant efforts to strengthen their infrastructure and enhance service offerings in this domain, with most of the initiatives undertaken in the last 12 months.
The rising interest in this market is reflected from the rising partnerships established among various stakeholders in the recent past; in fact, close to 60% of the deals were inked in the last three years.

More than 780 clinical trials have been registered till date to evaluate the safety and efficacy of various antibody drug conjugates; majority of these studies have been conducted across various sites in the US.
Various ADC therapeutic developers are anticipated to forge strategic alliances with contract manufacturing service providers in order to outsource complex manufacturing operations.
The deployment of ADCs requires the selection of antibody, linker, and cytotoxic payload, in order to target high-expression tumor antigens that are internalized by the cell.
Notably, over 30% of the total capacity expansion initiatives were carried out by the players located in North America, reflecting the region’s dominance in advanced ADC manufacturing infrastructure.
The global installed antibody drug conjugates manufacturing capacity is well distributed across various geographies; interestingly, around 90% of total installed capacity is available in facilities owned by large players.
The demand for ADC therapeutics is likely to increase significantly as several clinical candidates are expected to be commercialized across various regions.
Driven by the expanding pipeline of ADC therapeutics and manufacturing expertise available with contract service providers, the ADC contract manufacturing market is poised to witness significant growth in the future.

Europe currently dominates the market (45%) and captures the largest share within the ADC contract manufacturing market; this is followed by North America.
The humanized sub-segment is estimated to capture majority of the overall market share in the current year, owing to its enhanced safety and reduced immunogenicity.
The ADC contract manufacturing market in North America is expected to capture maximum share by 2035; further, close to 85% of the companies in this domain offer services for antibody manufacturing.

ADC CONTRACT MANUFACTURING MARKET: KEY SEGMENTS

Commercial Scale of Operation Accounts for the Largest Share of ADC Contract Manufacturing Market

In terms of scale of operation, the ADC contract manufacturing market is segmented across various scales of operation such as clinical and commercial scale. Currently, the commercial scale segment occupies the higher market share (around 90%), owing to the surging demand for ADCs as potent targeted cancer therapies. The clinical segment is likely to grow at a higher CAGR (7.6%) during the forecast period. This stems from many ADC drug candidates authorized by regulatory agencies since 2021. Advancements in ADC therapies have led to a growing quantity of ADCs moving into the clinical development phase.

Solid Tumors Segment to Hold the Highest Revenue in the ADC Contract Manufacturing Market

In the current year, solid tumors segment is likely to capture majority of the ADC contract manufacturing market size (with a share of 80%), and this trend is unlikely to change in the future as well. This prevalence arises from the fact that the majority of commercialized ADC therapeutics and those in advanced clinical trials specifically for solid tumors. The market for hematologic cancers is expected to expand at a CAGR of 8.7% during the forecast period.

Antibodies are Likely to Hold the Highest ADC Contract Manufacturing Market Share in the Future

In the current year, the antibody segment occupies the highest share in the overall market and this trend is expected to remain same during the forecast period. The higher share of antibodies is due to the complex cellular or protein engineering requirements, making antibody manufacturing a time and cost-intensive process, thus prompting the need for more specialized antibody manufacturing expertise.

Asia-Pacific is Likely to Propel the ADC Contract Manufacturing Market

The market in Asia-Pacific and rest of the world is likely to grow at a relatively higher CAGR (8.5%), during the forecast period. This is a result of significant cost advantage offered by this region, particularly in countries such as China and India, where lower labor costs and operational expenses provide favorable manufacturing environment as compared to traditional hubs in North America and Europe. Examples of ADC contract manufacturing companies based in Asia-Pacific include Shilpa Biologics, WuXi Biologics, Formosa Laboratories, Syngene and Samsung Biologics.

Example Players in the ADC Contract Manufacturing Market

AbbVie Contract Manufacturing
Abzena
CARBOGEN AMCIS
Catalent Pharma Solutions
Cerbios-Pharma
MabPlex
Millipore Sigma
Lonza
WuXi Biologics

Primary Research Overview

Discussions with multiple stakeholders in this domain influenced the opinions and insights presented in this study. The market report includes transcripts of the following discussions:

Senior Director, Commercial Development, Large company, Europe
Business Development Manager, Mid-sized company, Europe
Chief Executive Officer, Large company, Europe
Chief Executive Officer and Founder, Small Company, UK
Chief Executive Officer and Co-Founder, Small Company, France
Former Chief Executive Officer, Large Company, US
Chief Commercial Officer, Mid-sized Company, Switzerland
Chief Business Officer, Small Company, Switzerland
Executive Director, Large Company, Japan and Chief Innovation Officer, Large Company, Japan
Director, Business Development, Small Company, Netherlands
Director Corporate Development, Mid-sized Company, US
Director, Business Development, Large Company, US and Former Group Product Manager, Large Company, US
Former Director of CDMO, Large Organization, France
Business Development Manager, Mid-sized Company, Switzerland
Former Head of Bioconjugates Commercial Development, Large Company, Switzerland
Former Site Head, Large Company, US
Associate Scientist, Large Company, US

ADC CONTRACT MANUFACTURING MARKET: RESEARCH COVERAGE

Market Sizing and Opportunity Analysis: The report features an in-depth analysis of the ADC contract manufacturing market, focusing on key market segments, including [A] stage of development, [B] process component, [C] type of payload, [D] antibody isotype, [E] target indication, [F] antibody origin, [G] type of linker and [H] key geographical regions.
Market Landscape: A comprehensive evaluation of overall market landscape of players engaged in the contract manufacturing of ADCs, based on several relevant parameters, such as [A] year of establishment, [B] company size, [C] location of headquarters, [D] type of ADC manufacturing service offered, [E] type of additional service offered, [F] scale of and [G] location of manufacturing facility.
Company Profiles: In-depth profiles of companies engaged in the manufacturing of ADCs headquartered in North America, Europe and Asia-Pacific focusing on [A] company overview, [B] ADC contract manufacturing portfolio, [C] recent developments and [D] an informed future outlook.
Company Competitiveness Analysis: A comprehensive competitive analysis of ADC contract manufacturers, examining factors, such as [A] supplier strength, [B] service strength and [C] number of manufacturing facilities.
Partnerships and Collaborations: A detailed analysis of the partnerships inked between stakeholders in the ADC contract manufacturing market based on several relevant parameters, such as [A] year of partnership, [B] type of partnership, [C], year and type of partnership and [D], geographical distribution of partnership activity.
Recent Expansions: A detailed analysis of the recent expansions undertaken by various ADC contract manufacturers, based on several relevant parameters, such as [A] year of expansion, [B] type of expansion, [C] type of excipient, [D] type of expansion (region and country), [E] location of expanded facility (region), [F] location of expanded facility (country), [G] most active players (in terms of number of recent expansions) and [H] geographical distribution (region and country).
Capacity Analysis: An estimate of the global installed capacity for antibody contract manufacturing taking into consideration the capacities of various ADC contract manufacturers, based on several relevant parameters, such as [A] company size, [B] scale of operation and [C] key geographical regions.
Make Versus Buy Decision Making: A detailed evaluation of current and future opportunity within the ADC contract manufacturing market across different process components, such as [A] antibody, [B] HPAPI / cytotoxic payload, [C] conjugation / linker and [D] fill / finish.
Value Chain Analysis: A detailed discussion on various steps (antibody manufacturing, payload manufacturing, linker manufacturing, conjugation and fill / finish) involved in the manufacturing of ADCs, along with information on the cost requirements across each stage.
Case Study: An overview of the current market landscape of ADCs, along with detailed analysis of the ADCs pipeline, based on several relevant parameters, such as [A] status of development, [B] target disease indication, [C] therapeutic area, [D] line of treatment, [E] dosing frequency, [F] type of therapy, [G] target antigen, [H] antibody isotype, [I] payload / cytotoxin / warhead, [J] type of payload and [K] type of linker.
Clinical Trial Analysis: An in-depth analysis of completed, ongoing, and planned clinical studies of various ADCs, based on several relevant parameters, such as [A] trial registration year, [B] number of patients enrolled, [C] trial phase, [D] trial status, [E] target patient population, [F] patient gender, [G] type of sponsor / collaborator, [H] study design, [I] most active player (based on the number of registered trials) and [J] geography.
Likely Partners Analysis: An in-depth analysis of ADC therapy developers that are likely to partner with ADC contract manufacturers, based on several relevant parameters, such as [A] developer strength, [B] pipeline strength and [C] maturity and [D] manufacturing capabilities.
Demand Analysis: An informed estimate of the annual commercial and clinical demand for ADC therapeutics (in kilograms) based on, based on relevant parameters, such as [A] target patient population, [B] dosing frequency and [C] dose strength of approved products and [D] clinical stage candidates.
Regional Capability Analysis: A detailed regional capability assessment framework, which compares the key geographies, based on a number of parameters, such as the [A] number of ADC contract manufacturers, [B] number of ADC manufacturing facilities, [C] number of facility expansions, [D] installed ADC bioconjugation capacity, [E] number of registered clinical trials and [F] demand for ADCs in that particular geographical region.
Attractiveness Competitiveness Matrix: A detailed assessment of the current market scenario (in terms of existing competition and growth opportunities) across emerging and established market segments.
Market Impact Analysis: In-depth analysis of the factors that can impact the growth of the ADC contract manufacturing market. It also features identification and market analysis of [A] key drivers, [B] potential restraints, [C] emerging opportunities, and [D] existing challenges.

KEY QUESTIONS ANSWERED IN THIS REPORT

How many companies are currently engaged in this market?
Which are the leading companies in this market?
What factors are likely to influence the evolution of this market?
What is the current and future market size?
What is the CAGR of this market?
How is the current and future market opportunity likely to be distributed across key market segments?

REASONS TO BUY THIS REPORT

The report provides a comprehensive market analysis, offering detailed revenue projections of the overall market and its specific sub-segments. This information is valuable to both established market leaders and emerging entrants.
Stakeholders can leverage the report to gain a deeper understanding of the competitive dynamics within the market. By analyzing the competitive landscape, businesses can make informed decisions to optimize their market positioning and develop effective go-to-market strategies.
The report offers stakeholders a comprehensive overview of the market, including key drivers, barriers, opportunities, and challenges. This information empowers stakeholders to stay abreast of market trends and make data-driven decisions to capitalize on growth prospects.

ADDITIONAL BENEFITS

Complimentary Excel Data Packs Covering All Analytical Modules
Up to 15% Complimentary Content Customization
In-Depth Report Walkthrough with the Research Team
Complimentary Report Update if the Report is 6+ Months Old

1. PREFACE

1.1. Introduction
1.2. Market Share Insights
1.3. Key Market Insights
1.4. Report Coverage
1.5. Key Questions Answered
1.6. Chapter Outlines

2. RESEARCH METHODOLOGY

2.1. Chapter Overview
2.2. Research Assumptions
2.2.1. Market Landscape and Market Trends
2.2.2. Market Forecast and Opportunity Analysis
2.2.3. Comparative Analysis
2.3. Database Building
2.3.1. Data Collection
2.3.2. Data Validation
2.3.3. Data Analysis
2.4. Project Methodology
2.4.1. Secondary Research
2.4.1.1. Annual Reports
2.4.1.2. Academic Research Papers
2.4.1.3. Company Websites
2.4.1.4. Investor Presentations
2.4.1.5. Regulatory Filings
2.4.1.6. White Papers
2.4.1.7. Industry Publications
2.4.1.8. Conferences and Seminars
2.4.1.9. Government Portals
2.4.1.10. Media and Press Releases
2.4.1.11. Newsletters
2.4.1.12. Industry Databases
2.4.1.13. Roots Proprietary Databases
2.4.1.14. Paid Databases and Sources
2.4.1.15. Social Media Portals
2.4.1.16. Other Secondary Sources
2.4.2. Primary Research
2.4.2.1. Types of Primary Research
2.4.2.1.1. Qualitative Research
2.4.2.1.2. Quantitative Research
2.4.2.1.3. Hybrid Approach
2.4.2.2. Advantages of Primary Research
2.4.2.3. Techniques for Primary Research
2.4.2.3.1. Interviews
2.4.2.3.2. Surveys
2.4.2.3.3. Focus Groups
2.4.2.3.4. Observational Research
2.4.2.3.5. Social Media Interactions
2.4.2.4. Key Opinion Leaders Considered in Primary Research
2.4.2.4.1. Company Executives (CXOs)
2.4.2.4.2. Board of Directors
2.4.2.4.3. Company Presidents and Vice Presidents
2.4.2.4.4. Research and Development Heads
2.4.2.4.5. Technical Experts
2.4.2.4.6. Subject Matter Experts
2.4.2.4.7. Scientists
2.4.2.4.8. Doctors and Other Healthcare Providers
2.4.2.5. Ethics and Integrity
2.4.2.5.1. Research Ethics
2.4.2.5.2. Data Integrity
2.4.3. Analytical Tools and Databases
2.5. Robust Quality Control

3. MARKET DYNAMICS

3.1. Chapter Overview
3.2. Forecast Methodology
3.2.1. Top-down Approach
3.2.2. Bottom-up Approach
3.2.3. Hybrid Approach
3.3. Market Assessment Framework
3.3.1. Total Addressable Market (TAM)
3.3.2. Serviceable Addressable Market (SAM)
3.3.3. Serviceable Obtainable Market (SOM)
3.3.4. Currently Acquired Market (CAM)
3.4. Forecasting Tools and Techniques
3.4.1. Qualitative Forecasting
3.4.2. Correlation
3.4.3. Regression
3.4.4. Extrapolation
3.4.5. Convergence
3.4.6. Sensitivity Analysis
3.4.7. Scenario Planning
3.4.8. Data Visualization
3.4.9. Time Series Analysis
3.4.10. Forecast Error Analysis
3.5. Key Considerations
3.5.1. Demographics
3.5.2. Government Regulations
3.5.3. Reimbursement Scenarios
3.5.4. Market Access
3.5.5. Supply Chain
3.5.6. Industry Consolidation
3.5.7. Pandemic / Unforeseen Disruptions Impact
3.6. Limitations

4. MACRO-ECONOMIC INDICATORS

4.1. Chapter Overview
4.2. Market Dynamics
4.2.1. Time Period
4.2.1.1. Historical Trends
4.2.1.2. Current and Forecasted Estimates
4.2.2. Currency Coverage
4.2.2.1. Major Currencies Affecting the Market
4.2.2.2. Factors Affecting Currency Fluctuations on the Industry
4.2.2.3. Impact of Currency Fluctuations on the Industry
4.2.3. Foreign Currency Exchange Rate
4.2.3.1. Impact of Foreign Exchange Rate Volatility on the Market
4.2.3.2. Strategies for Mitigating Foreign Exchange Risk
4.2.4. Recession
4.2.4.1. Assessment of Current Economic Conditions and Potential Impact on the Market
4.2.4.2. Historical Analysis of Past Recessions and Lessons Learnt
4.2.5. Inflation
4.2.5.1. Measurement and Analysis of Inflationary Pressures in the Economy
4.2.5.2. Potential Impact of Inflation on the Market Evolution
4.2.6. Interest Rates
4.2.6.1. Interest Rates and Their Impact on the Market
4.2.6.2. Strategies for Managing Interest Rate Risk
4.2.7. Commodity Flow Analysis
4.2.7.1. Type of Commodity
4.2.7.2. Origins and Destinations
4.2.7.3. Value and Weights
4.2.7.4. Modes of Transportation
4.2.8. Global Trade Dynamics
4.2.8.1. Import Scenario
4.2.8.2. Export Scenario
4.2.8.3. Trade Policies
4.2.8.4. Strategies for Mitigating the Risks Associated with Trade Barriers
4.2.8.5. Impact of Trade Barriers on the Market
4.2.9. War Impact Analysis
4.2.9.1. Russian-Ukraine War
4.2.9.2. Israel-Hamas War
4.2.10. COVID Impact / Related Factors
4.2.10.1. Global Economic Impact
4.2.10.2. Industry-specific Impact
4.2.10.3. Government Response and Stimulus Measures
4.2.10.4. Future Outlook and Adaptation Strategies
4.2.11. Other Indicators
4.2.11.1. Fiscal Policy
4.2.11.2. Consumer Spending
4.2.11.3. Gross Domestic Product (GDP)
4.2.11.4. Employment
4.2.11.5. Taxes
4.2.11.6. Stock Market Performance
4.2.11.7. Cross-Border Dynamics
4.3. Conclusion

5. EXECUTIVE SUMMARY

6. INTRODUCTION

6.1. Chapter Overview
6.2. Key Components of ADCs
6.2.1. Antibody
6.2.2. Cytotoxin (Payloads)
6.2.3. Linker
6.3. ADC Manufacturing
6.3.1. Key Steps
6.3.2. Technical Challenges
6.3.3. Need for Outsourcing
6.4. Challenges Associated with Supply Chain and Method Transfer
6.4.1. Growing Demand for One-Stop-Shops and Integrated Service Providers
6.5. Selecting a CMO Partner
6.6. Future Perspective

7. MARKET LANDSCAPE

7.1. Chapter Overview
7.2. ADC Contract Manufacturers: Overall Market Landscape
7.2.1. Analysis by Year of Establishment
7.2.2. Analysis by Company Size
7.2.3. Analysis by Location of Headquarters
7.2.4. Analysis by Type of ADC Manufacturing Service Offered
7.2.5. Analysis by Type of Additional Service Offered
7.2.6. Analysis by Scale of Operation
7.2.7. Analysis by Location of Manufacturing Facility

8. COMPANY COMPETITIVENESS ANALYSIS

8.1. Chapter Overview
8.2. Assumptions and Key Parameters
8.3. Methodology
8.4. ADC Contract Manufacturers: Company Competitiveness Analysis
8.4.1. ADC Contract Manufacturers based in North America (Peer Group I)
8.4.2. ADC Contract Manufacturers based in Europe (Peer Group II)
8.4.3. ADC Contract Manufacturers based in Asia-Pacific (Peer Group III)
8.5. Capability Benchmarking of top ADC Contract Manufacturers

9. COMPANY PROFILES: ADC CONTRACT MANUFACTURERS

9.1. Chapter Overview
9.2. MabPlex
9.2.1. Company Overview
9.2.2. ADC Related Services
9.2.3. Manufacturing Facilities
9.2.4. Recent Developments and Future Outlook
9.3. Lonza
9.4. Abzena
9.5. GBI
9.6. CARBOGEN AMICS
9.7. Millipore Sigma
9.8. WuXi Biologics
9.9. Catalent Pharma Solutions
9.10. Cerbios-Pharma
9.11. Formosa Laboratories
9.12. Sterling Pharma Solutions
9.13. Piramal Pharma Solutions
9.14. AbbVie Contract Manufacturing

10. RECENT EXPANSIONS

10.1. Chapter Overview
10.2. ADC Contract Manufacturers: Recent Expansions
10.2.1. Analysis by Year of Expansion
10.2.2. Analysis by Type of Expansion
10.2.3. Analysis by Purpose of Expansion
10.2.4. Analysis by Type of Facility
10.2.5. Analysis by Scale of Operation
10.2.6. Analysis by Location of Expanded Facility
10.2.7. Most Active Players: Analysis by Number of Expansions

11. PARTNERSHIPS AND COLLABORATIONS

11.1. Chapter Overview
11.2. Partnership Models
11.3. ADC Contract Manufacturers: Partnerships and Collaborations
11.3.1. Analysis by Year of Partnership
11.3.2. Analysis by Type of Partnership
11.3.3. Analysis by Scale of Operation
11.3.4. Most Active Players: Analysis by Number of Partnerships
11.3.5. Analysis by Geography
11.3.5.1. Intercontinental and Intracontinental Agreements
11.3.5.2. Local and International Agreements

12. MAKE VERSUS BUY DECISION MAKING

12.1. Chapter Overview
12.2. Assumptions and Key Parameters
12.2.1. Scenario 1
12.2.2. Scenario 2
12.2.3. Scenario 3
12.2.4. Scenario 4
12.3. Concluding Remarks

13. VALUE CHAIN ANALYSIS

13.1. Chapter Overview
13.2. ADC Development Value Chain
13.3. Cost Distribution across the Value Chain
13.3.1. Cost Associated with Antibody Manufacturing
13.3.2. Cost Associated with Payload and Linker Manufacturing
13.3.3. Cost Associated with Conjugation
13.3.4. Cost Associated with Fill / Finish

14. CAPACITY ANALYSIS

14.1. Chapter Overview
14.2. Key Assumptions and Methodology
14.3. ADC Manufacturing: Global Installed Capacity
14.3.1. Analysis by Company Size
14.3.2. Analysis by Location of Headquarters
14.3.3. Analysis by Location of Manufacturing Facility
14.3.3.1. Analysis by Region
14.3.3.2. Analysis by Country
14.3.4. Analysis by Key Players

15. CASE STUDY: ADC THERAPEUTICS MARKET OVERVIEW

15.1. Chapter Overview
15.2. ADC Therapeutics: Therapies Pipeline
15.2.1. Analysis by Status of Development
15.2.2. Analysis by Target Disease Indication
15.2.3. Analysis by Therapeutic Area
15.2.4. Analysis by Line of Treatment
15.2.5. Analysis by Dosing Frequency
15.2.6. Analysis by Type of Therapy
15.2.7. Analysis by Target Antigen
15.2.8. Analysis by Antibody Isotype
15.2.9. Analysis by Payload / Cytotoxin / Warhead
15.2.10. Analysis by Type of Payload
15.2.11. Analysis by Linker
15.2.12. Analysis by Type of Linker (Cleavable / Non-Cleavable)
15.3. Antibody Drug Conjugates: Therapies to Watch
15.4. Concluding Remarks

16. CLINICAL TRIAL ANALYSIS

16.1. Chapter Overview
16.2. Scope and Methodology
16.3. Antibody Drug Conjugates: Clinical Trial Analysis
16.3.1. Analysis by Trial Registration Year
16.3.2. Analysis of Number of Patients Enrolled by Trial Registration Year
16.3.3. Analysis by Trial Phase
16.3.4. Analysis of Number of Patients Enrolled by Trial Phase
16.3.5. Analysis by Trial Status
16.3.6. Analysis by Trial Registration Year and Trial Status
16.3.7. Analysis of Number of Patients Enrolled by Trial Status
16.3.8. Analysis by Patient Gender
16.3.9. Analysis by Study Design
16.3.9.1. Analysis by Type of Allocation
16.3.9.2. Analysis by Type of Intervention Model
16.3.9.3. Analysis by Type of Masking
16.3.9.4. Analysis by Trial Purpose
16.3.10. Analysis by Type of Sponsor / Collaborator
16.3.11. Leading Industry Players: Analysis by Number of Clinical Trials
16.3.12. Leading Non-Industry Players: Analysis by Number of Clinical Trials
16.3.13. Analysis by Geography
16.3.13.1. Analysis of Clinical Trials by Geography
16.3.13.2. Analysis of Clinical Trials by Geography and Trial Status
16.3.13.3. Analysis of Patients Enrolled by Geography and Trial Status

17. LIKELY PARTNER ANALYSIS

17.1. Chapter Overview
17.2. Scoring Criteria and Key Assumptions
17.3. Scope and Methodology
17.4. Potential Strategic Partners based in North America
17.4.1. Most Likely Partners
17.4.2. Likely Partners
17.4.3. Least Likely Partners
17.5. Potential Strategic Partners based in Europe
17.5.1. Most Likely Partners
17.5.2. Likely Partners
17.5.3. Least Likely Partners
17.6. Potential Strategic Partners based in Asia-Pacific and Rest of the World
17.6.1. Most Likely Partners
17.6.2. Likely Partners
17.6.3. Least Likely Partners

18. ADC THERAPEUTICS: DEMAND ANALYSIS

18.1. Chapter Overview
18.2. Key Assumptions and Methodology
18.3. ADC Therapeutics: Global Annual Demand
18.3.1. ADC Therapeutics: Annual Commercial Demand
18.3.1.1. Analysis by Target Indication
18.3.1.2. Analysis by Antibody Origin
18.3.1.3. Analysis by Antibody Isotype
18.3.1.4. Analysis by Type of Payload
18.3.1.5. Analysis by Type of Linker
18.3.1.6. Analysis by Key Geographical Regions
18.3.2. ADC Therapeutics: Annual Clinical Demand
18.3.2.1. Analysis by Phase of Development
18.3.2.2. Analysis by Target Indication
18.3.2.3. Analysis by Antibody Origin
18.3.2.4. Analysis by Antibody Isotype
18.3.2.5. Analysis by Type of Payload
18.3.2.6. Analysis by Type of Linker
18.3.2.7. Analysis by Key Geographical Regions

19. REGIONAL CAPABILITY ANALYSIS

19.1. Chapter Overview
19.2. Assumptions and Key Parameters
19.3. ADC Contract Manufacturing Capabilities in North America
19.4. ADC Contract Manufacturing Capabilities in Europe
19.5. ADC Contract Manufacturing Capabilities in Asia-Pacific and Rest of the World

20. ATTRACTIVENESS COMPETITIVENESS MATRIX

20.1. Chapter Overview
20.2. AC Matrix: Overview
20.2.1. Strong Business Segments
20.2.2. Average Business Segments
20.2.3. Weak Business Segments
20.3. AC Matrix: Analytical Methodology
20.4. AC Matrix: Overall ADC Contract Manufacturing Market Scenario
20.4.1. AC Matrix: ADC Contract Manufacturing Scenario for Type of ADC Manufacturing Service Offered
20.4.2. AC Matrix: ADC Contract Manufacturing Scenario for Key Geographical Regions

21. MARKET IMPACT ANALYSIS

21.1. Chapter Overview
21.2. Market Drivers
21.3. Market Restraints
21.4. Market Opportunities
21.5. Market Challenges
21.6. Conclusion

22. GLOBAL ADC CONTRACT MANUFACTURING MARKET

22.1. Chapter Overview
22.2. Key Assumptions and Methodology
22.3. Global ADC Therapeutics Market: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
22.3.1. Scenario Analysis
22.3.1.1. Conservative Scenario
22.3.1.2. Optimistic Scenario
22.4. Key Market Segmentations

23. ADC CONTRACT MANUFACTURING MARKET, BY SCALE OF OPERATION

23.1. Chapter Overview
23.2. Key Assumptions and Methodology
23.3. ADC Contract Manufacturing Market: Distribution by Scale of Operation
23.3.1. ADC Contract Manufacturing Market for Clinical Scale, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
23.3.2. ADC Contract Manufacturing Market for Commercial Scale, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
23.4. Data Triangulation and Validation

24. ADC CONTRACT MANUFACTURING MARKET, BY PROCESS COMPONENT

24.1. Chapter Overview
24.2. Key Assumptions and Methodology
24.3. ADC Contract Manufacturing Market: Distribution by Process Component
24.3.1. ADC Contract Manufacturing Market for Antibodies, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
24.3.2. ADC Contract Manufacturing Market for HPAPI / Cytotoxic Payloads, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
24.3.3. ADC Contract Manufacturing Market for Conjugation / Linkers, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
24.3.4. ADC Contract Manufacturing Market for Fill / Finish, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
24.4. Data Triangulation and Validation

25. ADC CONTRACT MANUFACTURING MARKET, BY TYPE OF PAYLOAD

25.1. Chapter Overview
25.2. Key Assumptions and Methodology
25.3. ADC Contract Manufacturing Market: Distribution by Type of Payload
25.3.1. ADC Contract Manufacturing Market for Tubulin Inhibitors, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
25.3.2. ADC Contract Manufacturing Market for Topoisomerase Inhibitors, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
25.3.3. ADC Contract Manufacturing Market for DNA Damaging Agents, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
25.3.4. ADC Contract Manufacturing Market for Others, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
25.4. Data Triangulation and Validation

26. ADC CONTRACT MANUFACTURING MARKET, BY ANTIBODY ORIGIN

26.1. Chapter Overview
26.2. Key Assumptions and Methodology
26.3. ADC Contract Manufacturing Market: Distribution by Antibody Origin
26.3.1. ADC Contract Manufacturing Market for Humanized, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
26.3.2. ADC Contract Manufacturing Market for Chimeric, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
26.3.3. ADC Contract Manufacturing Market for Human, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
26.3.4. ADC Contract Manufacturing Market for Others, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
26.4. Data Triangulation and Validation

27. ADC CONTRACT MANUFACTURING MARKET, BY ANTIBODY ISOTYPE

27.1. Chapter Overview
27.2. Key Assumptions and Methodology
27.3. ADC Contract Manufacturing Market: Distribution by Antibody Isotype
27.3.1. ADC Contract Manufacturing Market for IgG1, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
27.3.2. ADC Contract Manufacturing Market for IgG4, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
27.3.3. ADC Contract Manufacturing Market for Others, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
27.4. Data Triangulation and Validation

28. ADC CONTRACT MANUFACTURING MARKET, BY TARGET INDICATION

28.1. Chapter Overview
28.2. Key Assumptions and Methodology
28.3. ADC Contract Manufacturing Market: Distribution by Target Indication
28.3.1. ADC Contract Manufacturing Market for Solid Tumors, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
28.3.2. ADC Contract Manufacturing Market for Hematological Malignancies, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
28.4. Data Triangulation and Validation

29. ADC CONTRACT MANUFACTURING MARKET, BY TYPE OF LINKER

29.1. Chapter Overview
29.2. Key Assumptions and Methodology
29.3. ADC Contract Manufacturing Market: Distribution by Type of Linker
29.3.1. ADC Contract Manufacturing Market for Valine-citrulline, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
29.3.2. ADC Contract Manufacturing Market for SMCC, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
29.3.3. ADC Contract Manufacturing Market for Hydrazone, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
29.3.4. ADC Contract Manufacturing Market for Maleimide, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
29.3.5. ADC Contract Manufacturing Market for Maleimidocaproyl, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
29.3.6. ADC Contract Manufacturing Market for Tetrapeptide-based Linkers, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
29.3.7. ADC Contract Manufacturing Market for Peptide Linkers, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
29.3.8. ADC Contract Manufacturing Market for Others, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
29.4. Data Triangulation and Validation

30. ADC CONTRACT MANUFACTURING MARKET, BY KEY GEOGRAPHICAL REGIONS

30.1. Chapter Overview
30.2. Key Assumptions and Methodology
30.3. ADC Contract Manufacturing Market: Distribution by Key Geographical Regions
30.3.1. ADC Contract Manufacturing Market in North America, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
30.3.1.1. ADC Contract Manufacturing Market in the US, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
30.3.1.2. ADC Contract Manufacturing Market in Canada, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
30.3.1.3. ADC Contract Manufacturing Market in Rest of North America, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
30.3.2. ADC Contract Manufacturing Market in Europe, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
30.3.2.1. ADC Contract Manufacturing Market in the UK, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
30.3.2.2. ADC Contract Manufacturing Market in Spain, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
30.3.2.3. ADC Contract Manufacturing Market in Italy, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
30.3.2.4. ADC Contract Manufacturing Market in Germany, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
30.3.2.5. ADC Contract Manufacturing Market in France, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
30.3.2.6. ADC Contract Manufacturing Market for Rest of Europe, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
30.3.3. ADC Contract Manufacturing Market in Asia-Pacific and Rest of the World, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
30.3.3.1. ADC Contract Manufacturing Market in China, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
30.3.3.2. ADC Contract Manufacturing Market in Japan, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
30.3.3.3. ADC Contract Manufacturing Market in India, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
30.3.3.4. ADC Contract Manufacturing Market in South Korea, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
30.3.3.5. ADC Contract Manufacturing Market for Australia, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
30.3.3.6. ADC Contract Manufacturing Market for Argentina, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
30.3.3.7. ADC Contract Manufacturing Market for Brazil, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
30.3.3.8. ADC Contract Manufacturing Market for Chile, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
30.3.3.9. ADC Contract Manufacturing Market for Colombia, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
30.3.3.10. ADC Contract Manufacturing Market for Israel, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
30.3.3.11. ADC Contract Manufacturing Market for Kenya, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
30.3.3.12. ADC Contract Manufacturing Market for Peru, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
30.3.3.13. ADC Contract Manufacturing Market for South Africa, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
30.3.3.14. ADC Contract Manufacturing Market for Turkey, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
30.3.3.15. ADC Contract Manufacturing Market for Saudi Arabia, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
30.3.3.16. ADC Contract Manufacturing Market for Other Countries, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
30.4. Data Triangulation and Validation

31. COMMERCIAL ADC CONTRACT MANUFACTURING MARKET

31.1. Chapter Overview
31.2. Key Assumptions and Methodology
31.3. Commercial ADC Contract Manufacturing Market: Forecasted Estimates (Till 2035)
31.3.1. Commercial ADC Contract Manufacturing Market: Distribution by Process Component, Forecasted Estimates (Till 2035)
31.3.2. Commercial ADC Contract Manufacturing Market: Distribution by Type of Payload, Forecasted Estimates (Till 2035)
31.3.3. Commercial ADC Contract Manufacturing Market: Distribution by Antibody Origin, Forecasted Estimates (Till 2035)
31.3.4. Commercial ADC Contract Manufacturing Market: Distribution by Antibody Isotype, Forecasted Estimates (Till 2035)
31.3.5. Commercial ADC Contract Manufacturing Market: Distribution by Target Indication, Forecasted Estimates (Till 2035)
31.3.6. Commercial ADC Contract Manufacturing Market: Distribution by Type of Linker, Forecasted Estimates (Till 2035)
31.3.7. Commercial ADC Contract Manufacturing Market: Distribution by Key Geographical Regions, Forecasted Estimates (Till 2035)
31.4. Data Triangulation and Validation

32. CLINICAL ADC CONTRACT MANUFACTURING MARKET

32.1. Chapter Overview
32.2. Key Assumptions and Methodology
32.3. Clinical ADC Contract Manufacturing Market: Forecasted Estimates (Till 2035)
32.3.1. Clinical ADC Contract Manufacturing Market: Distribution by Phase of Development, Forecasted Estimates (Till 2035)
32.3.2. Clinical ADC Contract Manufacturing Market: Distribution by Process Component, Forecasted Estimates (Till 2035)
32.3.3. Clinical ADC Contract Manufacturing Market: Distribution by Type of Payload, Forecasted Estimates (Till 2035)
32.3.4. Clinical ADC Contract Manufacturing Market: Distribution by Antibody Origin, Forecasted Estimates (Till 2035)
32.3.5. Clinical ADC Contract Manufacturing Market: Distribution by Antibody Isotype, Forecasted Estimates (Till 2035)
32.3.6. Clinical ADC Contract Manufacturing Market: Distribution by Target Indication, Forecasted Estimates (Till 2035)
32.3.7. Clinical ADC Contract Manufacturing Market: Distribution by Type of Linker, Forecasted Estimates (Till 2035)
32.3.8. Clinical ADC Contract Manufacturing Market: Distribution by Key Geographical Regions, Forecasted Estimates (Till 2035)
32.4. Data Triangulation and Validation

33. CONCLUDING REMARKS

34. EXECUTIVE INSIGHTS

34.1. Chapter Overview
34.2. Company A
34.2.1. Company Snapshot
34.2.2. Interview Transcript: Business Development Manager
34.3. Company B
34.3.1. Company Snapshot
34.3.2. Interview Transcript: Chief Executive Officer and Technical Business Development Manager
34.4. Company C
34.4.1. Company Snapshot
34.4.2. Interview Transcript: Chief Commercial Officer
34.5. Company D
34.5.1. Company Snapshot
34.5.2. Interview Transcript: Associate Scientist,
34.6. Company E
34.6.1. Company Snapshot
34.6.2. Interview Transcript: Former Director Corporate Development
34.7. Company F
34.7.1. Company Snapshot
34.7.2. Interview Transcript: Executive Director and Takashi Owa, Chief Innovation Officer
34.8. Company G
34.8.1. Company Snapshot
34.8.2. Interview Transcript: Former Chief Business Officer
34.9. Company H
34.9.1. Company Snapshot
34.9.2. Interview Transcript: Former Director of CDMO
34.10. Company I
34.10.1. Company Snapshot
34.10.2. Interview Transcript: Director, Business Development
34.11. Company J
34.11.1. Company Snapshot
34.11.2. Interview Transcript: Chief Executive Officer and Co-Founder
34.12. Company K
34.12.1. Company Snapshot
34.12.2. Interview Transcript: Former Site Head
34.13. Company L
34.13.1. Company Snapshot
34.13.2. Interview Transcript: Chief Executive Officer and Founder
34.14. Company M
34.14.1. Company Snapshot
34.14.2. Interview Transcript: Former Chief Executive Officer
34.15. Company N
34.15.1. Company Snapshot
34.15.2. Interview Transcript: Former Director, Business Development and Former Group Product Manager
34.16. Company O
34.16.1. Company Snapshot
34.16.2. Interview Transcript: Former Head of Bioconjugates Commercial Development
34.17. Company P
34.17.1. Company Snapshot
34.17.2. Interview Transcript: Senior Director, Commercial Development and Marketing Strategy Bioconjugates

35. APPENDIX I: TABULATED DATA36. APPENDIX II: LIST OF COMPANIES AND ORGANIZATION

LIST OF FIGURES

Figure 2.1 Research Methodology: Project Methodology
Figure 2.2 Research Methodology: Data Sources for Secondary Research
Figure 2.3 Research Methodology: Robust Quality Control
Figure 3.1 Market Dynamics: Forecast Methodology
Figure 3.2 Market Dynamics: Market Assessment Framework
Figure 4.1 Lessons Learnt from Past Recessions
Figure 5.1 Executive Summary: Market Landscape
Figure 5.2 Executive Summary: Market Trends
Figure 5.3 Executive Summary: Capacity and Demand Analysis
Figure 5.4 Executive Summary: Market Forecast and Opportunity Analysis
Figure 6.1 Key Components of an ADC
Figure 6.2 ADC Manufacturing Steps
Figure 6.3 Key Parameters while Selecting a CMO Partner
Figure 7.1 ADC Contract Manufacturers: Distribution by Year of Establishment
Figure 7.2 ADC Contract Manufacturers: Distribution by Company Size
Figure 7.3 ADC Contract Manufacturers: Distribution by Location of Headquarters
Figure 7.4 ADC Contract Manufacturers: Distribution by Type of ADC Manufacturing Service Offered
Figure 7.5 ADC Contract Manufacturers: Distribution by Type of Additional Service Offered
Figure 7.6 ADC Contract Manufacturers: Distribution by Scale of Operation
Figure 7.7 ADC Contract Manufacturers: Distribution by Location of Manufacturing Facility
Figure 8.1 Company Competitiveness Analysis: Overview of Peer Group I
Figure 8.2 Company Competitiveness Analysis: Overview of Peer Group II
Figure 8.3 Company Competitiveness Analysis: Overview of Peer Group III
Figure 8.4 Company Competitiveness Analysis: ADC Contract Manufacturing Services Offered by Companies based in North America
Figure 8.5 Company Competitiveness Analysis: ADC Contract Manufacturing Services Offered by Companies based in Europe
Figure 8.6 Company Competitiveness Analysis: ADC Contract Manufacturing Services Offered by Companies based in Asia-Pacific
Figure 9.1 Lonza: Annual Revenues, (YEN Billion), Since 2021
Figure 9.2 WuXi Biologics: Annual Revenues, (CHF Billion), Since 2021
Figure 9.3 Catalent Pharma Solutions: Annual Revenues, (USD Billion), Since 2021
Figure 10.1 Recent Expansions: Distribution by Year of Expansion
Figure 10.2 Recent Expansions: Distribution by Type of Expansion
Figure 10.3 Recent Expansions: Distribution by Purpose of Expansion
Figure 10.4 Recent Expansions: Distribution by Type of Facility
Figure 10.5 Recent Expansions: Distribution by Scale of Operation
Figure 10.6 Recent Expansions: Distribution by Location of Expanded Facility
Figure 10.7 Most Active Players: Distribution by Number of Expansion Initiatives
Figure 11.1 Partnerships and Collaborations: Distribution by Year of Partnership
Figure 11.2 Partnerships and Collaborations: Distribution by Type of Partnership
Figure 11.3 Partnerships and Collaborations: Distribution by Year and Type of Partnership
Figure 11.4 Partnerships and Collaborations: Distribution by Purpose of Partnership
Figure 11.5 Partnerships and Collaborations: Distribution by Scale of Operation
Figure 11.6 Most Active Players: Distribution by Number of Partnerships
Figure 11.7 Partnerships and Collaborations: Intercontinental and Intracontinental Agreements
Figure 11.8 Partnerships and Collaborations: Local and International Agreements
Figure 12.1 Make versus Buy Decision Making Framework
Figure 12.2 Make versus Buy Decision Making: Possible Scenario Descriptions
Figure 13.1 Value Chain Analysis: ADC Development Overview
Figure 13.2 Value Chain Analysis: ADC Contract Manufacturing Overview
Figure 13.3 ADC Therapeutics: Distribution by Cost of Raw Material Required for Clinical Stage Manufacturing
Figure 13.4 Value Chain Analysis: Distribution by Cost
Figure 13.5 Costs Associated with Antibody Manufacturing
Figure 13.6 Costs Associated with Payload and Linker Manufacturing
Figure 13.7 Costs Associated with Conjugation
Figure 13.8 Costs Associated with Fill / Finish
Figure 14.1 Global Installed ADC Manufacturing Capacity: Distribution by Company Size
Figure 14.2 Global Installed ADC Manufacturing Capacity: Distribution by Location of Headquarters
Figure 14.3 Global Installed ADC Manufacturing Capacity: Distribution by Location of Manufacturing Facility (Region)
Figure 14.4 Global Installed ADC Manufacturing Capacity: Distribution by Location of Manufacturing Facility (Country)
Figure 14.5 Global Installed ADC Manufacturing Capacity: Distribution by Key Players
Figure 15.1 ADC Therapeutics: Distribution by Status of Development
Figure 15.2 ADC Therapeutics: Distribution by Target Disease Indication
Figure 15.3 ADC Therapeutics: Distribution by Therapeutic Area
Figure 15.4 ADC Therapeutics: Distribution by Line of Treatment
Figure 15.5 ADC Therapeutics: Distribution by Dosing Frequency
Figure 15.6 ADC Therapeutics: Distribution by Type of Therapy
Figure 15.7 ADC Therapeutics: Distribution by Target Antigen
Figure 15.8 ADC Therapeutics: Distribution by Antibody Isotype
Figure 15.9 ADC Therapeutics: Distribution by Payload / Cytotoxin / Warhead
Figure 15.10 ADC Therapeutics: Distribution by Type of Payload
Figure 15.11 ADC Therapeutics: Distribution by Linker
Figure 15.12 ADC Therapeutics: Distribution by Type of Linker
Figure 16.1 Clinical Trial Analysis: Cumulative Year-wise Trend, Since 2021
Figure 16.2 Clinical Trial Analysis: Distribution of Number of Patients Enrolled by Trial Registration Year, Since 2021
Figure 16.3 Clinical Trial Analysis: Distribution by Trial Phase
Figure 16.4 Clinical Trial Analysis: Distribution of Number of Patients Enrolled by Trial Phase
Figure 16.5 Clinical Trial Analysis: Distribution by Trial Status
Figure 16.6 Clinical Trial Analysis: Distribution by Trial Registration Year and Trial Status, Since 2021
Figure 16.7 Clinical Trial Analysis: Distribution of Number of Patients Enrolled by Trial Status
Figure 16.8 Clinical Trial Analysis: Distribution by Patient Gender
Figure 16.9 Clinical Trial Analysis: Distribution by Type of Allocation
Figure 16.10 Clinical Trial Analysis: Distribution by Type of Intervention Model
Figure 16.11 Clinical Trial Analysis: Distribution by Type of Masking
Figure 16.12 Clinical Trial Analysis: Distribution by Trial Purpose
Figure 16.13 Clinical Trial Analysis: Distribution by Type of Sponsor / Collaborator
Figure 16.14 Leading Industry Players: Distribution by Number of Clinical Trials
Figure 16.15 Leading Non-Industry Players: Distribution by Number of Clinical Trials
Figure 16.16 Clinical Trial Analysis: Distribution of Clinical Trials by Geography
Figure 16.17 Clinical Trial Analysis: Distribution of Clinical Trials by Geography and Trial Status
Figure 16.18 Clinical Trial Analysis: Distribution of Patients Enrolled by Geography and Trial Status
Figure 18.1 Global Demand for ADC Therapeutics, till 2035 (in kg)
Figure 18.2 Global Demand for ADC Therapeutics: Distribution by Stage of Development, till 2035 (in kg)
Figure 18.3 Global Commercial Demand for ADC Therapeutics, till 2035 (in kg)
Figure 18.4 Global Commercial Demand for ADC Therapeutics: Distribution by Target Indication, till 2035 (in kg)
Figure 18.5 Global Commercial Demand for ADC Therapeutics: Distribution by Antibody Origin, till 2035 (in kg)
Figure 18.6 Global Commercial Demand for ADC Therapeutics: Distribution by Antibody Isotype, till 2035 (in kg)
Figure 18.7 Global Commercial Demand for ADC Therapeutics: Distribution by Type of Payload, till 2035 (in kg)
Figure 18.8 Global Commercial Demand for ADC Therapeutics: Distribution by Type of Linker, till 2035 (in kg)
Figure 18.9 Global Commercial Demand for ADC Therapeutics: Distribution by Key Geographical Regions, till 2035 (in kg)
Figure 18.10 Global Clinical Demand for ADC Therapeutics, till 2035 (in kg)
Figure 18.11 Global Clinical Demand for ADC Therapeutics: Distribution by Phase of Development, till 2035 (in kg)
Figure 18.12 Global Clinical Demand for ADC Therapeutics: Distribution by Target Indication, till 2035 (in kg)
Figure 18.13 Global Clinical Demand for ADC Therapeutics: Distribution by Antibody Origin, till 2035 (in kg)
Figure 18.14 Global Clinical Demand for ADC Therapeutics: Distribution by Antibody Isotype, till 2035 (in kg)
Figure 18.15 Global Clinical Demand for ADC Therapeutics: Distribution by Type of Payload, till 2035 (in kg)
Figure 18.16 Global Clinical Demand for ADC Therapeutics: Distribution by Type of Linker, till 2035 (in kg)
Figure 18.17 Global Clinical Demand for ADC Therapeutics: Distribution by Key Geographical Regions, till 2035 (in kg)
Figure 19.1 Regional Capability Analysis: ADC Contract Manufacturing Capabilities in North America
Figure 19.2 Regional Capability Analysis: ADC Contract Manufacturing Capabilities in Europe
Figure 19.3 Regional Capability Analysis: ADC Contract Manufacturing Capabilities in Asia-Pacific and Rest of the World
Figure 20.1 AC Matrix: Pictorial Representation
Figure 20.2 AC Matrix: Overall ADC Contract Manufacturing Market Scenario (Till 2035)
Figure 20.3 AC Matrix: ADC Contract Manufacturing Scenario for Type of ADC Manufacturing Service Offered
Figure 20.4 AC Matrix: ADC Contract Manufacturing Scenario for Key Geographical Regions
Figure 22.1 Global ADC Contract Manufacturing Market, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035): Base Scenario (USD Billion)
Figure 22.2 Global ADC Contract Manufacturing Market, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035): Conservative Scenario (USD Billion)
Figure 22.3 Global ADC Contract Manufacturing Market, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035): Optimistic Scenario (USD Billion)
Figure 23.1 ADC Contract Manufacturing Market: Distribution by Scale of Operation
Figure 23.2 ADC Contract Manufacturing Market for Clinical Scale: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) (USD Billion)
Figure 23.3 ADC Contract Manufacturing Market for Commercial Scale: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) (USD Billion)
Figure 24.1 ADC Contract Manufacturing Market: Distribution by Process Component
Figure 24.2 ADC Contract Manufacturing Market for Antibodies: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) (USD Billion)
Figure 24.3 ADC Contract Manufacturing Market for HPAPI / Cytotoxic Payloads: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) (USD Billion)
Figure 24.4 ADC Contract Manufacturing Market for Conjugation / Linkers: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) (USD Billion)
Figure 24.5 ADC Contract Manufacturing Market for Fill / Finish: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) (USD Billion)
Figure 25.1 ADC Contract Manufacturing Market: Distribution by Type of Payload
Figure 25.2 ADC Contract Manufacturing Market for Tubulin Inhibitors: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) (USD Billion)
Figure 25.3 ADC Contract Manufacturing Market for Topoisomerase Inhibitors: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) (USD Billion)
Figure 25.4 ADC Contract Manufacturing Market for DNA Damaging Agents: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) (USD Billion)
Figure 25.5 ADC Contract Manufacturing Market for Others: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) (USD Billion)
Figure 26.1 ADC Contract Manufacturing Market: Distribution by Antibody Origin
Figure 26.2 ADC Contract Manufacturing Market for Humanized: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) (USD Billion)
Figure 26.3 ADC Contract Manufacturing Market for Chimeric: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) (USD Billion)
Figure 26.4 ADC Contract Manufacturing Market for Human: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) (USD Billion)
Figure 26.5 ADC Contract Manufacturing Market for Others: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) (USD Billion)
Figure 27.1 ADC Contract Manufacturing Market: Distribution by Antibody Isotype
Figure 27.2 ADC Contract Manufacturing Market for IgG1: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) (USD Billion)
Figure 27.3 ADC Contract Manufacturing Market for IgG4: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) (USD Billion)
Figure 27.4 ADC Contract Manufacturing Market for Others: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) (USD Billion)
Figure 28.1 ADC Contract Manufacturing Market: Distribution by Target Indication
Figure 28.2 ADC Contract Manufacturing Market for Solid Tumors: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) (USD Billion)
Figure 28.3 ADC Contract Manufacturing Market for Hematological Malignancies: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) (USD Billion)
Figure 29.1 ADC Contract Manufacturing Market: Distribution by Type of Linker
Figure 29.2 ADC Contract Manufacturing Market for Valine-citrulline: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) (USD Billion)
Figure 29.3 ADC Contract Manufacturing Market for SMCC: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) (USD Billion)
Figure 29.4 ADC Contract Manufacturing Market for Hydrazone: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) (USD Billion)
Figure 29.5 ADC Contract Manufacturing Market for Maleimide: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) (USD Billion)
Figure 29.6 ADC Contract Manufacturing Market for Maleimidocaproyl: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) (USD Billion)
Figure 29.7 ADC Contract Manufacturing Market for Tetrapeptide-based Linkers: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) (USD Billion)
Figure 29.8 ADC Contract Manufacturing Market for Peptide Linkers: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) (USD Billion)
Figure 29.9 ADC Contract Manufacturing Market for Others: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) (USD Billion)
Figure 30.1 ADC Contract Manufacturing Market: Distribution by Key Geographical Regions
Figure 30.2 ADC Contract Manufacturing Market in North America: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) (USD Billion)
Figure 30.3 ADC Contract Manufacturing Market in the US: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) (USD Billion)
Figure 30.4 ADC Contract Manufacturing Market in Canada: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) (USD Billion)
Figure 30.5 ADC Contract Manufacturing Market in Rest of North America: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) (USD Billion)
Figure 30.6 ADC Contract Manufacturing Market in Europe: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) (USD Billion)
Figure 30.7 ADC Contract Manufacturing Market in the UK: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) (USD Billion)
Figure 30.8 ADC Contract Manufacturing Market in Spain: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) (USD Billion)
Figure 30.9 ADC Contract Manufacturing Market in Italy: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) (USD Billion)
Figure 30.10 ADC Contract Manufacturing Market in Germany: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) (USD Billion)
Figure 30.11 ADC Contract Manufacturing Market in France: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) (USD Billion)
Figure 30.12 ADC Contract Manufacturing Market in Rest of Europe: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) (USD Billion)
Figure 30.13 ADC Contract Manufacturing Market in Asia-Pacific and Rest of the World: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) (USD Billion)
Figure 30.14 ADC Contract Manufacturing Market in China: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) (USD Billion)
Figure 30.15 ADC Contract Manufacturing Market in Japan: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) (USD Billion)
Figure 30.16 ADC Contract Manufacturing Market in India: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) (USD Billion)
Figure 30.17 ADC Contract Manufacturing Market in South Korea: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) (USD Billion)
Figure 30.18 ADC Contract Manufacturing Market in Australia: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) (USD Billion)
Figure 30.19 ADC Contract Manufacturing Market in Argentina: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) (USD Billion)
Figure 30.20 ADC Contract Manufacturing Market in Brazil: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) (USD Billion)
Figure 30.21 ADC Contract Manufacturing Market in Chile: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) (USD Billion)
Figure 30.22 ADC Contract Manufacturing Market in Colombia: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) (USD Billion)
Figure 30.23 ADC Contract Manufacturing Market in Israel: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) (USD Billion)
Figure 30.24 ADC Contract Manufacturing Market in Kenya: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) (USD Billion)
Figure 30.25 ADC Contract Manufacturing Market in Peru: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) (USD Billion)
Figure 30.26 ADC Contract Manufacturing Market in South Africa: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) (USD Billion)
Figure 30.27 ADC Contract Manufacturing Market in Turkey: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) (USD Billion)
Figure 30.28 ADC Contract Manufacturing Market in Saudi Arabia: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) (USD Billion)
Figure 30.29 ADC Contract Manufacturing Market in Other Countries: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) (USD Billion)
Figure 31.1 Commercial ADC Contract Manufacturing Market, Forecasted Estimates, till 2035 (USD Million)
Figure 31.2 Commercial ADC Contract Manufacturing Market: Distribution by Process Component, Forecasted Estimates, till 2035 (USD Million)
Figure 31.3 Commercial ADC Contract Manufacturing Market: Distribution by Type of Payload, Forecasted Estimates, till 2035 (USD Million)
Figure 31.4 Commercial ADC Contract Manufacturing Market: Distribution by Antibody Origin, Forecasted Estimates, till 2035 (USD Million)
Figure 31.5 Commercial ADC Contract Manufacturing Market: Distribution by Antibody Isotype, Forecasted Estimates, till 2035 (USD Million)
Figure 31.6 Commercial ADC Contract Manufacturing Market: Distribution by Target Indication, Forecasted Estimates, till 2035 (USD Million)
Figure 31.7 Commercial ADC Contract Manufacturing Market: Distribution by Type of Linker, Forecasted Estimates, till 2035 (USD Million)
Figure 31.8 Commercial ADC Contract Manufacturing Market: Distribution by Key Geographical Regions, Forecasted Estimates, till 2035 (USD Million)
Figure 32.1 Clinical ADC Contract Manufacturing Market, Forecasted Estimates, till 2035 (USD Million)
Figure 32.2 Clinical ADC Contract Manufacturing Market: Distribution by Phase of Development, Forecasted Estimates, till 2035 (USD Million)
Figure 32.3 Clinical ADC Contract Manufacturing Market: Distribution by Process Component, Forecasted Estimates, till 2035 (USD Million)
Figure 32.4 Clinical ADC Contract Manufacturing Market: Distribution by Type of Payload, Forecasted Estimates, till 2035 (USD Million)
Figure 32.5 Clinical ADC Contract Manufacturing Market: Distribution by Antibody Origin, Forecasted Estimates, till 2035 (USD Million)
Figure 32.6 Clinical ADC Contract Manufacturing Market: Distribution by Antibody Isotype, Forecasted Estimates, till 2035 (USD Million)
Figure 32.7 Clinical ADC Contract Manufacturing Market: Distribution by Target Indication, Forecasted Estimates, till 2035 (USD Million)
Figure 32.8 Clinical ADC Contract Manufacturing Market: Distribution by Type of Linker, Forecasted Estimates, till 2035 (USD Million)
Figure 32.9 Clinical ADC Contract Manufacturing Market: Distribution by Key Geographical Regions, Forecasted Estimates, till 2035 (USD Million)
Figure 33.1 Concluding Remarks: Market Landscape
Figure 33.2 Concluding Remarks: Recent Expansions
Figure 33.3 Concluding Remarks: Partnerships and Collaborations
Figure 33.4 Concluding Remarks: Clinical Trial Analysis
Figure 33.5 Concluding Remarks: Likely Partner Analysis
Figure 33.6 Concluding Remarks: Capacity Analysis
Figure 33.7 Concluding Remarks: Demand Analysis
Figure 33.8 Concluding Remarks: Market Sizing and Opportunity Analysis (1/3)
Figure 33.9 Concluding Remarks: Market Sizing and Opportunity Analysis (2/3)
Figure 33.10 Concluding Remarks: Market Sizing and Opportunity Analysis (3/3)

LIST OF TABLES

Table 6.1 Common Cytotoxins used for the Production of ADCs
Table 6.2 Safebridge Categorization / OEL Bands for Highly Potent / Cytotoxic Compounds
Table 7.1 ADC Contract Manufacturers: Information on Year of Establishment, Company Size, and Location of Headquarters
Table 7.2 ADC Contract Manufacturers: Information on Type of ADC Manufacturing Service Offered
Table 7.3 ADC Contract Manufacturers: Information on Type of Additional Service Offered and Scale of Operation
Table 7.4 ADC Contract Manufacturers: Information on Location of Manufacturing Facility
Table 9.1 ADC Contract Manufacturers: List of Companies Profiled
Table 9.2 MabPlex: Company Overview
Table 9.3 MabPlex: ADC Related Services
Table 9.4 MabPlex: Information on Manufacturing Facilities
Table 9.5 Lonza: Company Overview
Table 9.6 Lonza: ADC Related Services
Table 9.7 Lonza: Information on Manufacturing Facilities
Table 9.8 Lonza: Recent Developments and Future Outlook
Table 9.9 Abzena: Company Overview
Table 9.10 Abzena: ADC Related Services
Table 9.11 Abzena: Information on Manufacturing Facilities
Table 9.12 Abzena: Recent Developments and Future Outlook
Table 9.13 GBI: Company Overview
Table 9.14 GBI: ADC Related Services
Table 9.15 GBI: Information on Manufacturing Facilities
Table 9.16 CARBOGEN AMCIS: Company Overview
Table 9.17 CARBOGEN AMCIS: ADC Related Services
Table 9.18 CARBOGEN AMCIS: Information on Manufacturing Facilities
Table 9.19 CARBOGEN AMCIS: Recent Developments and Future Outlook
Table 9.20 Millipore Sigma: Company Overview
Table 9.21 Millipore Sigma: ADC Related Services
Table 9.22 Millipore Sigma: Information on Manufacturing Facilities
Table 9.23 WuXi Biologics: Company Overview
Table 9.24 WuXi Biologics: ADC Related Services
Table 9.25 WuXi Biologics: Information on Manufacturing Facilities
Table 9.26 WuXi Biologics: Recent Developments and Future Outlook
Table 9.27 Catalent Pharma Solutions: Company Overview
Table 9.28 Catalent Pharma Solutions: ADC Related Services
Table 9.29 Catalent Pharma Solutions: Information on Manufacturing Facilities
Table 9.30 Catalent Pharma Solutions: Recent Developments and Future Outlook
Table 9.31 Cerbios-Pharma: Company Overview
Table 9.32 Cerbios-Pharma: ADC Related Services
Table 9.33 Cerbios-Pharma: Information on Manufacturing Facilities
Table 9.34 Cerbios-Pharma: Recent Developments and Future Outlook
Table 9.35 Formosa Laboratories: Company Overview
Table 9.36 Formosa Laboratories: ADC Related Services
Table 9.37 Formosa Laboratories: Information on Manufacturing Facilities
Table 9.38 Sterling Pharma Solutions: Company Overview
Table 9.39 Sterling Pharma Solutions: ADC Related Services
Table 9.40 Sterling Pharma Solutions: Information on Manufacturing Facilities
Table 9.41 Sterling Pharma Solutions: Recent Developments and Future Outlook
Table 9.42 Piramal Pharma Solutions: Company Overview
Table 9.43 Piramal Pharma Solutions: ADC Related Services
Table 9.44 Piramal Pharma Solutions: Information on Manufacturing Facilities
Table 9.45 Piramal Pharma Solutions: Recent Developments and Future Outlook
Table 9.46 AbbVie Contract Manufacturing: Company Overview
Table 9.47 AbbVie Contract Manufacturing: ADC Related Services
Table 9.48 AbbVie Contract Manufacturing: Information on Manufacturing Facilities
Table 10.1 ADC Contract Manufacturers: Information on Year of Expansion, Type of Expansion, Purpose of Expansion, and Type of Facility, Since 2019
Table 10.2 ADC Contract Manufacturers: Information on Location of Expanded Facility and Scale of Operation
Table 11.1 ADC Contract Manufacturers: Information on Year of Partnership, Type of Partnership, and Scale of Operation, Since 2020
Table 13.1 ADC Components: Information on Cost of Cytotoxins
Table 13.2 ADC Components: Information on Cost of Linkers
Table 14.1 Global Installed ADC Contract Manufacturing Capacity: Sample Data Set (Yield)
Table 14.2 Global Installed ADC Contract Manufacturing Capacity: Sample Data Set (Average Capacity)
Table 14.3 Global Installed ADC Manufacturing Capacity: Information on Total Capacity based on Company Size
Table 15.1 ADC Therapeutics: Information on Drug Candidates, Developers, Status of Development, Target Disease Indication and Therapeutic Area
Table 15.2 ADC Therapeutics to Watch: Information on Drug Candidates, Developer, Status of Development, Target Disease Indication and Therapeutic Area
Table 17.1 Most Likely Partners based in North America
Table 17.2 Likely Partners based in North America
Table 17.3 Least Likely Partners based in North America
Table 17.4 Most Likely Partners based in Europe
Table 17.5 Likely Partners based in Europe
Table 17.6 Least Likely Partners based in Europe
Table 17.7 Most Likely Partners based in Asia-Pacific and Rest of the World
Table 17.8 Likely Partners based in Asia-Pacific and Rest of the World
Table 17.9 Least Likely Partners based in Asia-Pacific and Rest of the World
Table 18.1 List of Late Stage ADCs
Table 34.1 Cerbios-Pharma: Key Highlights
Table 34.2 BSP Biopharmaceuticals: Key Highlights
Table 34.3 Cerbios-Pharma: Key Highlights
Table 34.4 Ajinomoto Bio-Pharma Services: Key Highlights
Table 34.5 GBI: Key Highlights
Table 34.6 Eisai: Key Highlights
Table 34.7 NBE-Therapeutics: Key Highlights
Table 34.8 Pierre Fabre: Key Highlights
Table 34.9 Synaffix: Key Highlights
Table 6.3 Common Cytotoxins used for the Production of ADCs
Table 6.4 Safebridge Categorization / OEL Bands for Highly Potent / Cytotoxic Compounds
Table 7.5 ADC Contract Manufacturers: Information on Year of Establishment, Company Size, and Location of Headquarters
Table 7.6 ADC Contract Manufacturers: Information on Type of ADC Manufacturing Service Offered
Table 7.7 ADC Contract Manufacturers: Information on Type of Additional Service Offered and Scale of Operation
Table 7.8 ADC Contract Manufacturers: Information on Location of Manufacturing Facility
Table 9.49 ADC Contract Manufacturers: List of Companies Profiled
Table 9.50 MabPlex: Company Overview
Table 9.51 MabPlex: ADC Related Services
Table 9.52 MabPlex: Information on Manufacturing Facilities
Table 9.53 Lonza: Company Overview
Table 9.54 Lonza: ADC Related Services
Table 9.55 Lonza: Information on Manufacturing Facilities
Table 9.56 Lonza: Recent Developments and Future Outlook
Table 9.57 Abzena: Company Overview
Table 9.58 Abzena: ADC Related Services
Table 9.59 Abzena: Information on Manufacturing Facilities
Table 9.60 Abzena: Recent Developments and Future Outlook
Table 9.61 GBI: Company Overview
Table 9.62 GBI: ADC Related Services
Table 9.63 GBI: Information on Manufacturing Facilities
Table 9.64 CARBOGEN AMCIS: Company Overview
Table 9.65 CARBOGEN AMCIS: ADC Related Services
Table 9.66 CARBOGEN AMCIS: Information on Manufacturing Facilities
Table 9.67 CARBOGEN AMCIS: Recent Developments and Future Outlook
Table 9.68 Millipore Sigma: Company Overview
Table 9.69 Millipore Sigma: ADC Related Services
Table 9.70 Millipore Sigma: Information on Manufacturing Facilities
Table 9.71 WuXi Biologics: Company Overview
Table 9.72 WuXi Biologics: ADC Related Services
Table 9.73 WuXi Biologics: Information on Manufacturing Facilities
Table 9.74 WuXi Biologics: Recent Developments and Future Outlook
Table 9.75 Catalent Pharma Solutions: Company Overview
Table 9.76 Catalent Pharma Solutions: ADC Related Services
Table 9.77 Catalent Pharma Solutions: Information on Manufacturing Facilities
Table 9.78 Catalent Pharma Solutions: Recent Developments and Future Outlook
Table 9.79 Cerbios-Pharma: Company Overview
Table 9.80 Cerbios-Pharma: ADC Related Services
Table 9.81 Cerbios-Pharma: Information on Manufacturing Facilities
Table 9.82 Cerbios-Pharma: Recent Developments and Future Outlook
Table 9.83 Formosa Laboratories: Company Overview
Table 9.84 Formosa Laboratories: ADC Related Services
Table 9.85 Formosa Laboratories: Information on Manufacturing Facilities
Table 9.86 Sterling Pharma Solutions: Company Overview
Table 9.87 Sterling Pharma Solutions: ADC Related Services
Table 9.88 Sterling Pharma Solutions: Information on Manufacturing Facilities
Table 9.89 Sterling Pharma Solutions: Recent Developments and Future Outlook
Table 9.90 Piramal Pharma Solutions: Company Overview
Table 9.91 Piramal Pharma Solutions: ADC Related Services
Table 9.92 Piramal Pharma Solutions: Information on Manufacturing Facilities
Table 9.93 Piramal Pharma Solutions: Recent Developments and Future Outlook
Table 9.94 AbbVie Contract Manufacturing: Company Overview
Table 9.95 AbbVie Contract Manufacturing: ADC Related Services
Table 9.96 AbbVie Contract Manufacturing: Information on Manufacturing Facilities
Table 10.3 ADC Contract Manufacturers: Information on Year of Expansion, Type of Expansion, Purpose of Expansion, and Type of Facility, Since 2019
Table 10.4 ADC Contract Manufacturers: Information on Location of Expanded Facility and Scale of Operation
Table 11.2 ADC Contract Manufacturers: Information on Year of Partnership, Type of Partnership, and Scale of Operation, Since 2020
Table 13.3 ADC Components: Information on Cost of Cytotoxins
Table 13.4 ADC Components: Information on Cost of Linkers
Table 14.4 Global Installed ADC Contract Manufacturing Capacity: Sample Data Set (Yield)
Table 14.5 Global Installed ADC Contract Manufacturing Capacity: Sample Data Set (Average Capacity)
Table 14.6 Global Installed ADC Manufacturing Capacity: Information on Total Capacity based on Company Size
Table 15.3 ADC Therapeutics: Information on Drug Candidates, Developers, Status of Development, Target Disease Indication and Therapeutic Area
Table 15.4 ADC Therapeutics to Watch: Information on Drug Candidates, Developer, Status of Development, Target Disease Indication and Therapeutic Area
Table 17.10 Most Likely Partners based in North America
Table 17.11 Likely Partners based in North America
Table 17.12 Least Likely Partners based in North America
Table 17.13 Most Likely Partners based in Europe
Table 17.14 Likely Partners based in Europe
Table 17.15 Least Likely Partners based in Europe
Table 17.16 Most Likely Partners based in Asia-Pacific and Rest of the World
Table 17.17 Likely Partners based in Asia-Pacific and Rest of the World
Table 17.18 Least Likely Partners based in Asia-Pacific and Rest of the World
Table 18.2 List of Late Stage ADCs
Table 34.10 Cerbios-Pharma: Key Highlights
Table 34.11 BSP Biopharmaceuticals: Key Highlights
Table 34.12 Cerbios-Pharma: Key Highlights
Table 34.13 Ajinomoto Bio-Pharma Services: Key Highlights
Table 34.14 GBI: Key Highlights
Table 34.15 Eisai: Key Highlights
Table 34.16 NBE-Therapeutics: Key Highlights
Table 34.17 Pierre Fabre: Key Highlights
Table 34.18 Synaffix: Key Highlights
Table 34.19 Syndivia: Key Highlights
Table 34.20 Piramal Pharma Solutions: Key Highlights
Table 34.21 Oxford BioTherapeutics: Key Highlights
Table 34.22 Abzena: Key Highlights
Table 34.23 Catalent Pharma Solutions: Key Highlights
Table 34.24 Lonza: Key Highlights
Table 34.25 Lonza: Key Highlights
Table 35.1 ADC Contract Manufacturers: Distribution by Year of Establishment
Table 35.2 ADC Contract Manufacturers: Distribution by Company Size
Table 35.3 ADC Contract Manufacturers: Distribution by Location of Headquarters
Table 35.4 ADC Contract Manufacturers: Distribution by Type of ADC Manufacturing Service Offered
Table 35.5 ADC Contract Manufacturers: Distribution by Type of Additional Service Offered
Table 35.6 ADC Contract Manufacturers: Distribution by Scale of Operation
Table 35.7 ADC Contract Manufacturers: Distribution by Location of Manufacturing Facility
Table 35.8 Lonza: Annual Revenues, (YEN Billion), Since 2021
Table 35.9 WuXi Biologics: Annual Revenues, (CHF Billion), Since 2021
Table 35.10 Catalent Pharma Solutions: Annual Revenues, (USD Billion), Since 2021
Table 35.11 Recent Expansions: Distribution by Year of Expansion
Table 35.12 Recent Expansions: Distribution by Type of Expansion
Table 35.13 Recent Expansions: Distribution by Purpose of Expansion
Table 35.14 Recent Expansions: Distribution by Type of Facility
Table 35.15 Recent Expansions: Distribution by Scale of Operation
Table 35.16 Recent Expansions: Distribution by Location of Expanded Facility
Table 35.17 Most Active Players: Distribution by Number of Expansion Initiatives
Table 35.18 Partnerships and Collaborations: Distribution by Year of Partnership
Table 35.19 Partnerships and Collaborations: Distribution by Type of Partnership
Table 35.20 Partnerships and Collaborations: Distribution by Year and Type of Partnership
Table 35.21 Partnerships and Collaborations: Distribution by Purpose of Partnership
Table 35.22 Partnerships and Collaborations: Distribution by Scale of Operation
Table 35.23 Most Active Players: Distribution by Number of Partnerships
Table 35.24 Global Installed ADC Manufacturing Capacity: Distribution by Company Size
Table 35.25 Global Installed ADC Manufacturing Capacity: Distribution by Location of Headquarters
Table 35.26 Global Installed ADC Manufacturing Capacity: Distribution by Location of Manufacturing Facility (Region)
Table 35.27 Global Installed ADC Manufacturing Capacity: Distribution by Location of Manufacturing Facility (Country)
Table 35.28 Global Installed ADC Manufacturing Capacity: Distribution by Key Players
Table 35.29 ADC Therapeutics: Distribution by Status of Development
Table 35.30 ADC Therapeutics: Distribution by Target Disease Indication
Table 35.31 ADC Therapeutics: Distribution by Therapeutic Area
Table 35.32 ADC Therapeutics: Distribution by Line of Treatment
Table 35.33 ADC Therapeutics: Distribution by Dosing Frequency
Table 35.34 ADC Therapeutics: Distribution by Type of Therapy
Table 35.35 ADC Therapeutics: Distribution by Target Antigen
Table 35.36 ADC Therapeutics: Distribution by Antibody Isotype
Table 35.37 ADC Therapeutics: Distribution by Payload / Cytotoxin / Warhead
Table 35.38 ADC Therapeutics: Distribution by Type of Payload
Table 35.39 ADC Therapeutics: Distribution by Linker
Table 35.40 ADC Therapeutics: Distribution by Type of Linker
Table 35.41 Clinical Trial Analysis: Cumulative Year-wise Trend, Since 2021
Table 35.42 Clinical Trial Analysis: Distribution of Number of Patients Enrolled by Trial Registration Year, Since 2021
Table 35.43 Clinical Trial Analysis: Distribution by Trial Phase
Table 35.44 Clinical Trial Analysis: Distribution of Number of Patients Enrolled by Trial Phase
Table 35.45 Clinical Trial Analysis: Distribution by Trial Status
Table 35.46 Clinical Trial Analysis: Distribution by Trial Registration Year and Trial Status, Since 2021
Table 35.47 Clinical Trial Analysis: Distribution of Number of Patients Enrolled by Trial Status
Table 35.48 Clinical Trial Analysis: Distribution by Patient Gender
Table 35.49 Clinical Trial Analysis: Distribution by Type of Allocation
Table 35.50 Clinical Trial Analysis: Distribution by Type of Intervention Model
Table 35.51 Clinical Trial Analysis: Distribution by Type of Masking
Table 35.52 Clinical Trial Analysis: Distribution by Trial Purpose
Table 35.53 Clinical Trial Analysis: Distribution by Type of Sponsor / Collaborator
Table 35.54 Leading Industry Players: Distribution by Number of Clinical Trials
Table 35.55 Leading Non-Industry Players: Distribution by Number of Clinical Trials
Table 35.56 Clinical Trial Analysis: Distribution of Clinical Trials by Geography
Table 35.57 Clinical Trial Analysis: Distribution of Clinical Trials by Geography and Trial Status
Table 35.58 Clinical Trial Analysis: Distribution of Patients Enrolled by Geography and Trial Status
Table 35.59 Global Demand for ADC Therapeutics, till 2035 (in kg)
Table 35.60 Global Demand for ADC Therapeutics: Distribution by Stage of Development, till 2035 (in kg)
Table 35.61 Global Commercial Demand for ADC Therapeutics, till 2035 (in kg)
Table 35.62 Global Commercial Demand for ADC Therapeutics: Distribution by Target Indication, till 2035 (in kg)
Table 35.63 Global Commercial Demand for ADC Therapeutics: Distribution by Antibody Origin, till 2035 (in kg)
Table 35.64 Global Commercial Demand for ADC Therapeutics: Distribution by Antibody Isotype, till 2035 (in kg)
Table 35.65 Global Commercial Demand for ADC Therapeutics: Distribution by Type of Payload, till 2035 (in kg)
Table 35.66 Global Commercial Demand for ADC Therapeutics: Distribution by Type of Linker, till 2035 (in kg)
Table 35.67 Global Commercial Demand for ADC Therapeutics: Distribution by Key Geographical Regions, till 2035 (in kg)
Table 35.68 Global Clinical Demand for ADC Therapeutics, till 2035 (in kg)
Table 35.69 Global Clinical Demand for ADC Therapeutics: Distribution by Phase of Development, till 2035 (in kg)
Table 35.70 Global Clinical Demand for ADC Therapeutics: Distribution by Target Indication, till 2035 (in kg)
Table 35.71 Global Clinical Demand for ADC Therapeutics: Distribution by Antibody Origin, till 2035 (in kg)
Table 35.72 Global Clinical Demand for ADC Therapeutics: Distribution by Antibody Isotype, till 2035 (in kg)
Table 35.73 Global Clinical Demand for ADC Therapeutics: Distribution by Type of Payload, till 2035 (in kg)
Table 35.74 Global Clinical Demand for ADC Therapeutics: Distribution by Type of Linker, till 2035 (in kg)
Table 35.75 Global Clinical Demand for ADC Therapeutics: Distribution by Key Geographical Regions, till 2035 (in kg)
Table 35.76 Regional Capability Analysis: ADC Contract Manufacturing Capabilities in North America
Table 35.77 Regional Capability Analysis: ADC Contract Manufacturing Capabilities in Europe
Table 35.78 Regional Capability Analysis: ADC Contract Manufacturing Capabilities in Asia-Pacific and Rest of the World
Table 35.79 Global ADC Contract Manufacturing Market, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035): Base Scenario (USD Billion)
Table 35.80 Global ADC Contract Manufacturing Market, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035): Conservative Scenario (USD Billion)
Table 35.81 Global ADC Contract Manufacturing Market, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035): Optimistic Scenario (USD Billion)
Table 35.82 Global ADC Contract Manufacturing Market: Distribution by Scale of Operation
Table 35.83 ADC Contract Manufacturing Market for Clinical Scale: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) (USD Billion)
Table 35.84 ADC Contract Manufacturing Market for Commercial Scale: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) (USD Billion)
Table 35.85 ADC Contract Manufacturing Market: Distribution by Process Component
Table 35.86 ADC Contract Manufacturing Market for Antibodies: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) (USD Billion)
Table 35.87 ADC Contract Manufacturing Market for HPAPI / Cytotoxic Payloads: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) (USD Billion)
Table 35.88 ADC Contract Manufacturing Market for Conjugation / Linkers: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) (USD Billion)
Table 35.89 ADC Contract Manufacturing Market for Fill / Finish: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) (USD Billion)
Table 35.90 ADC Contract Manufacturing Market: Distribution by Type of Payload
Table 35.91 ADC Contract Manufacturing Market for Tubulin Inhibitors: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) (USD Billion)
Table 35.92 ADC Contract Manufacturing Market for Topoisomerase Inhibitors: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) (USD Billion)
Table 35.93 ADC Contract Manufacturing Market for DNA Damaging Agents: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) (USD Billion)
Table 35.94 ADC Contract Manufacturing Market for Others: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) (USD Billion)
Table 35.95 ADC Contract Manufacturing Market: Distribution by Antibody Origin
Table 35.96 ADC Contract Manufacturing Market for Humanized: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) (USD Billion)
Table 35.97 ADC Contract Manufacturing Market for Chimeric: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) (USD Billion)
Table 35.98 ADC Contract Manufacturing Market for Human: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) (USD Billion)
Table 35.99 ADC Contract Manufacturing Market for Others: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) (USD Billion)
Table 35.100 ADC Contract Manufacturing Market: Distribution by Antibody Isotype
Table 35.101 ADC Contract Manufacturing Market for IgG1: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) (USD Billion)
Table 35.102 ADC Contract Manufacturing Market for IgG4: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) (USD Billion)
Table 35.103 ADC Contract Manufacturing Market for Others: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) (USD Billion)
Table 35.104 ADC Contract Manufacturing Market: Distribution by Target Indication
Table 35.105 ADC Contract Manufacturing Market for Solid Tumors: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) (USD Billion)
Table 35.106 ADC Contract Manufacturing Market for Hematological Malignancies: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) (USD Billion)
Table 35.107 ADC Contract Manufacturing Market: Distribution by Type of Linker
Table 35.108 ADC Contract Manufacturing Market for Valine-citrulline: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) (USD Billion)
Table 35.109 ADC Contract Manufacturing Market for SMCC: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) (USD Billion)
Table 35.110 ADC Contract Manufacturing Market for Hydrazone SMCC: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) (USD Billion)
Table 35.111 ADC Contract Manufacturing Market for Maleimide: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) (USD Billion)
Table 35.112 ADC Contract Manufacturing Market for Maleimidocaproyl: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) (USD Billion)
Table 35.113 ADC Contract Manufacturing Market for Tetrapeptide-based Linkers: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) (USD Billion)
Table 35.114 ADC Contract Manufacturing Market for Peptide Linkers: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) (USD Billion)
Table 35.115 ADC Contract Manufacturing Market for Others: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) (USD Billion)
Table 35.116 ADC Contract Manufacturing Market: Distribution by Key Geographical Regions
Table 35.117 ADC Contract Manufacturing Market in North America: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) (USD Billion)
Table 35.118 ADC Contract Manufacturing Market in the US: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) (USD Billion)
Table 35.119 ADC Contract Manufacturing Market in Canada: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) (USD Billion)
Table 35.120 ADC Contract Manufacturing Market in Rest of North America: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) (USD Billion)
Table 35.121 ADC Contract Manufacturing Market in Europe: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) (USD Billion)
Table 35.122 ADC Contract Manufacturing Market in the UK: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) (USD Billion)
Table 35.123 ADC Contract Manufacturing Market in Spain: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) (USD Billion)
Table 35.124 ADC Contract Manufacturing Market in Italy: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) (USD Billion)
Table 35.125 ADC Contract Manufacturing Market in Germany: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) (USD Billion)
Table 35.126 ADC Contract Manufacturing Market in France: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) (USD Billion)
Table 35.127 ADC Contract Manufacturing Market in Rest of Europe: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) (USD Billion)
Table 35.128 ADC Contract Manufacturing Market in Asia-Pacific and Rest of the World: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) (USD Billion)
Table 35.129 ADC Contract Manufacturing Market in China: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) (USD Billion)
Table 35.130 ADC Contract Manufacturing Market in Japan: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) (USD Billion)
Table 35.131 ADC Contract Manufacturing Market in India: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) (USD Billion)
Table 35.132 ADC Contract Manufacturing Market in South Korea: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) (USD Billion)
Table 35.133 ADC Contract Manufacturing Market in Australia: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) (USD Billion)
Table 35.134 ADC Contract Manufacturing Market in Argentina: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) (USD Billion)
Table 35.135 ADC Contract Manufacturing Market in Brazil: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) (USD Billion)
Table 35.136 ADC Contract Manufacturing Market in Chile: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) (USD Billion)
Table 35.137 ADC Contract Manufacturing Market in Colombia: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) (USD Billion)
Table 35.138 ADC Contract Manufacturing Market in Israel: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) (USD Billion)
Table 35.139 ADC Contract Manufacturing Market in Kenya: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) (USD Billion)
Table 35.140 ADC Contract Manufacturing Market in Peru: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) (USD Billion)
Table 35.141 ADC Contract Manufacturing Market in South Africa: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) (USD Billion)
Table 35.142 ADC Contract Manufacturing Market in Turkey: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) (USD Billion)
Table 35.143 ADC Contract Manufacturing Market in Saudi Arabia: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) (USD Billion)
Table 35.144 ADC Contract Manufacturing Market in Other Countries: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) (USD Billion)
Table 35.145 Commercial ADC Contract Manufacturing Market, Forecasted Estimates, till 2035 (USD Million)
Table 35.146 Commercial ADC Contract Manufacturing Market: Distribution by Process Component, Forecasted Estimates, till 2035 (USD Million)
Table 35.147 Commercial ADC Contract Manufacturing Market: Distribution by Type of Payload, Forecasted Estimates, till 2035 (USD Million)
Table 35.148 Commercial ADC Contract Manufacturing Market: Distribution by Antibody Origin, Forecasted Estimates, till 2035 (USD Million)
Table 35.149 Commercial ADC Contract Manufacturing Market: Distribution by Antibody Isotype, Forecasted Estimates, till 2035 (USD Million)
Table 35.150 Commercial ADC Contract Manufacturing Market: Distribution by Target Indication, Forecasted Estimates, till 2035 (USD Million)
Table 35.151 Commercial ADC Contract Manufacturing Market: Distribution by Type of Linker, Forecasted Estimates, till 2035 (USD Million)
Table 35.152 Commercial ADC Contract Manufacturing Market: Distribution by Key Geographical Regions, Forecasted Estimates, till 2035 (USD Million)
Table 35.153 Clinical ADC Contract Manufacturing Market, Forecasted Estimates, till 2035 (USD Million)
Table 35.154 Clinical ADC Contract Manufacturing Market: Distribution by Phase of Development, Forecasted Estimates, till 2035 (USD Million)
Table 35.155 Clinical ADC Contract Manufacturing Market: Distribution by Process Component, Forecasted Estimates, till 2035 (USD Million)
Table 35.156 Clinical ADC Contract Manufacturing Market: Distribution by Type of Payload, Forecasted Estimates, till 2035 (USD Million)
Table 35.157 Clinical ADC Contract Manufacturing Market: Distribution by Antibody Origin, Forecasted Estimates, till 2035 (USD Million)
Table 35.158 Clinical ADC Contract Manufacturing Market: Distribution by Antibody Isotype, Forecasted Estimates, till 2035 (USD Million)
Table 35.159 Clinical ADC Contract Manufacturing Market: Distribution by Target Indication, Forecasted Estimates, till 2035 (USD Million)
Table 35.160 Clinical ADC Contract Manufacturing Market: Distribution by Type of Linker, Forecasted Estimates, till 2035 (USD Million)
Table 35.161 Clinical ADC Contract Manufacturing Market: Distribution by Key Geographical Regions, Forecasted Estimates, till 2035 (USD Million)

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

AbbVie
AbbVie Contract Manufacturing
ABL Bio
AbTis
Abzena
ACES Pharma
ADC Biotechnology (Acquired by Sterling Pharma Solutions)
ADC Therapeutics
Adcentrx Therapeutics
AIMEDBIO
Ajinomoto
Ajinomoto Bio-Pharma Services
Almac
Alphamab Oncology
ALSA Ventures
Alteogen
Ambrx
Amgen
Angiex
Araris Biotech
Asana BioSciences
Astellas Pharma
AstraZeneca
ATB Therapeutics
Atreca
Avipep Therapeutics
Axplora
Bayer
BeiGene
Bicycle Therapeutics
BioAtla
Biocytogen
BioMed Valley Discoveries
BiOneCure Therapeutics
Bioqube Ventures
Biosion
Bio-Synthesis
Bio-Thera Solutions
BiVictriX Therapeutics
BOC Sciences
Bolt Biotherapeutics
Boostimmune
Bristol-Myers Squibb
BSP Pharmaceuticals
Byondis
Cambrex
CARBOGEN AMCIS
Catalent Pharma Solutions
Celltrion
Centrose
Cerbios-Pharma
ChemPartner
Corbus Pharmaceuticals
Creative Biolabs
Cristal Therapeutics
CSPC Pharmaceutical
CStone Pharmaceuticals
CureMeta
CytomX Therapeutics
Daiichi Sankyo
Dalton Pharma Services
Dantari
Debiopharm
Diatheva
Duality Biologics
Eisai
Elevation Oncology
EMD Serono
Emergence Therapeutics
Exelixis
Farmabios
Formosa Laboratories
Formosa Pharmaceuticals
Fortis Therapeutics
Fosun Pharma
GBI
Genentech
GeneQuantum Healthcare
Genmab
Genor Biopharma
Gilead Sciences
Glycotope
GSK
GTP Bioways
Hangzhou Adcoris BioPharma
Hangzhou DAC Biotech
Harbour BioMed
Heidelberg Pharma
Hisun Pharmaceuticals
Hummingbird Bioscience
Iconic Therapeutics
Iksuda Therapeutics
ImmuneOncia Therapeutics
ImmunoBiochem
ImmunoGen
Immunome
Innovent Biologics
IntoCell
iProgen Biotech
KLUS Pharma (Subsidiary of Kelun-Biotech)
Kodiak Sciences
LaNova Medicines
LegoChem Biosciences
Lepu Biopharma
Levena Biopharma
Light Chain Bioscience
Lonza
Luzsana Biotechnology
Mablink Bioscience
MabPlex
Mabwell (Shanghai) Bioscience
Mabwell Therapeutics
MacroGenics
Magenta Therapeutics
McSAF
MediaPharma
MediLink Therapeutics
Megalith Pharmaceuticals
Menarini
Merck
Mersana Therapeutics
MilliporeSigma
Mitsubishi Tanabe Pharma
MuseChem
Mythic Therapeutics
NanoValent Pharmaceuticals
Navrogen
NBE-Therapeutics
Nordic Nanovector
NovaRock Biotherapeutics
Novartis
Novasep
NovoCodex Biopharmaceuticals
OBI Pharma
OGD2 Pharma
Oncolinx
Oncomatryx Biopharma
OnCusp Therapeutics
Orano Med
Oxford BioTherapeutics
Paul Scherrer Institute
Peak Bio
Perseus Proteomics
Pfizer
Pheon Therapeutics
Pierre Fabre Laboratories
PinotBio
Piramal Pharma Solutions
ProfoundBio
Pyxis Oncology
Rakuten Medical
Recipharm
Regeneron
RemeGen
Samsung Biologics
Sanofi
Sartorius
Schengen Pharma
Seagen
Shanghai Fudan Zhangjiang Biopharmaceutical
Shanghai Pharmaceuticals
Shanghai Hansoh Biomedical
Singzyme
Sorrento Therapeutics
SOTIO Biotech
Sterling Pharma Solutions
Sutro Biopharma
Symbiosis Pharmaceutical Services
Synaffix
Syngene
SystImmune
Takeda
Takeda Oncology
Tanabe Research Laboratories
Targinta (Subsidiary of Xintela)
Toray Industries
TOT BIOPHARM
TRIO Pharmaceuticals
Triphase Accelerator
Tubulis
UCB
University Medical Center Groningen
Vincerx Pharma
Veranova
WuXi Biologics
WuXi STA (A subsidiary of WuXi AppTec)
Y-Biologics
Zhejiang Teruisi Pharmaceutical
Zydus Lifesciences
Zymeworks

Methodology

LOADING...

License	Format	Properties	Price
SINGLE USER LICENSE PDF and Excel	The electronic report will be emailed to you. The file formats are PDF and Excel.	This is a single user license, allowing one user access to the product.	€4296EUR$4,799USD£3,752GBP
SITE LICENSE PDF and Excel	The electronic report will be emailed to you. The file formats are PDF and Excel.	This is a site license, allowing all users within a given geographical location of your organization access to the product.	€6265EUR$6,999USD£5,472GBP
ENTERPRISE LICENSE PDF and Excel	The electronic report will be emailed to you. The file formats are PDF and Excel.	This is an enterprise license, allowing all employees within your organization access to the product.	€16111EUR$17,999USD£14,073GBP

ADC Contract Manufacturing Market (7th Edition): Distribution by Stage of Development, Process Component, Type of Payload, Antibody Isotype, Target Indication, Antibody Origin, Type of Linker, and Key Geographical Regions - Industry Trends and Forecast 2025-2035

Scale of Operation

Process Component

Type of Payload

Antibody Isotype

Target Indication

Type of Linker

Antibody Origin

Key Geographical Regions

ADC CONTRACT MANUFACTURING MARKET: GROWTH AND TRENDS

ADC CONTRACT MANUFACTURING MARKET: KEY INSIGHTS

The report delves into the current state of the ADC contract manufacturing market and identifies potential growth opportunities within the industry. Some key findings from the report include:

ADC CONTRACT MANUFACTURING MARKET: KEY SEGMENTS

Commercial Scale of Operation Accounts for the Largest Share of ADC Contract Manufacturing Market

Solid Tumors Segment to Hold the Highest Revenue in the ADC Contract Manufacturing Market

Antibodies are Likely to Hold the Highest ADC Contract Manufacturing Market Share in the Future

Asia-Pacific is Likely to Propel the ADC Contract Manufacturing Market

Example Players in the ADC Contract Manufacturing Market

Primary Research Overview

Discussions with multiple stakeholders in this domain influenced the opinions and insights presented in this study. The market report includes transcripts of the following discussions:

ADC CONTRACT MANUFACTURING MARKET: RESEARCH COVERAGE

KEY QUESTIONS ANSWERED IN THIS REPORT

REASONS TO BUY THIS REPORT

ADDITIONAL BENEFITS

Table of Contents

Companies Mentioned (Partial List)

Methodology

Scale of Operation

Process Component

Type of Payload

Antibody Isotype

Target Indication

Type of Linker

Antibody Origin

Key Geographical Regions

ADC CONTRACT MANUFACTURING MARKET: GROWTH AND TRENDS

ADC CONTRACT MANUFACTURING MARKET: KEY INSIGHTS

The report delves into the current state of the ADC contract manufacturing market and identifies potential growth opportunities within the industry. Some key findings from the report include:

ADC CONTRACT MANUFACTURING MARKET: KEY SEGMENTS

Commercial Scale of Operation Accounts for the Largest Share of ADC Contract Manufacturing Market

Solid Tumors Segment to Hold the Highest Revenue in the ADC Contract Manufacturing Market

Antibodies are Likely to Hold the Highest ADC Contract Manufacturing Market Share in the Future

Asia-Pacific is Likely to Propel the ADC Contract Manufacturing Market

Example Players in the ADC Contract Manufacturing Market

Primary Research Overview

Discussions with multiple stakeholders in this domain influenced the opinions and insights presented in this study. The market report includes transcripts of the following discussions:

ADC CONTRACT MANUFACTURING MARKET: RESEARCH COVERAGE

KEY QUESTIONS ANSWERED IN THIS REPORT

REASONS TO BUY THIS REPORT

ADDITIONAL BENEFITS

Table of Contents

Companies Mentioned (Partial List)

Methodology

Related Topics

Related Reports

Antibody Drug Conjugates Contract Manufacturing Market Report 2026

Antibody Drug Conjugates Contract Manufacturing - Global Strategic Business Report

ADC Contract Manufacturing Market Report: Trends, Forecast and Competitive Analysis to 2031

Antibody Drug Conjugates Contract Manufacturing Market - Global Forecast 2026-2032

High Potency API Contract Manufacturing Market Outlook 2026-2034: Market Share, and Growth Analysis

About the Market